CHRONIC MYELOID LEUKAEMIA: EPIDEMIOLOGY DATA (2002–2007)
Povzetek
BACKGROUND Chronic myeloid leukaemia (CML) is a rare clonal neoplastic disease of hematopoieticstem cells. Epidemiology data of CML patients in Slovenia are presented. METHODS Data about all new patients with CML in the period from 2002 to 2007 were obtained fromall Slovenian hospitals with haematological department. RESULTS 90 patients were studied during the period of 6 years. The incidence was 0.75/100,000 onaverage. 14 patients (15 %) died. Incidence in male population was 4 % higher as infemale population. The patient population (average age 50.6 in males and 59.1 in femalesat the diagnosis of CML, respectively) was distributed also according to Slovenian statistical regions. The majority of patients was identified in the chronic phase of disease (83 %),being treated in recent years with imatinib (up to 85 % in 2007). CONCLUSIONS The incidence, as well as the average age of the patients with CML in Slovenia is lowercompared with data from the literature. The majority of patients are identified in earlystage of the disease and are treated in accordance with current guidelinesPrenosi
Prenosi
Objavljeno
Številka
Rubrika
Licenca
Avtor na prispevku, ki ga bo pripravil za Zdravniški vestnik, po pogodbi nanj prenaša vse materialne avtorske pravice, kakor izhajajo iz 22. člena Zakona o avtorski in sorodnih pravicah, in sicer pravico reproduciranja, pravico javnega izvajanja, pravico javnega prenašanja, pravico javnega predvajanja s fonogrami in videogrami, pravico javnega prikazovanja, pravico radiodifuznega oddajanja, pravico radiodifuzne retransmisije, pravico sekundarnega radiodifuznega oddajanja, pravico dajanja na voljo javnosti, pravico predelave, pravico avdiovizualne priredbe, pravico distribuiranja ter pravico dajanja v najem in vse druge pravice avtorja v skladu z ZASP.
Avtorjev prenos pravic po pogodbi je neizključen, velja za neomejeno število izdaj, za ves čas trajanja materialnih avtorskih pravic ter je prostorsko neomejen.
Avtor sme avtorsko delo tudi sam izkoriščati ali avtorske pravice prenašati na tretje osebe, vendar oboje šele po preteku 3 mesecev od prve objave dela v reviji Zdravniški vestnik.
Avtor Zdravniškemu vestniku izrecno dovoli, da lahko pravice, pridobljene v skladu s pogodbo prenaša naprej na tretje osebe brez omejitev.
Avtor se strinja, da Zdravniški vestnik prispevek objavi pod pogoji licence Creative Commons BY-NC 4.0 (navedba avtorstva-nekomercialno) ali primerljive licence.